Tau and Aβ imaging, CSF measures, and cognition in Alzheimer’s disease
Open accessThe DOI matches its Crossref record; 55 of the 56 references it cites were found in a registry or an index.
Abstract
PET imaging of pathological tau correlates more closely with Alzheimer’s disease–related cognitive impairment than does imaging of β-amyloid.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These previous studies suggest that CSF tau biomarkers and Tau PET reflect different aspects of tau pathology and may become abnormal at different stages of the disease.”
From Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive tau PET in Alzheimer's disease (2020) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Elevated tau PET binding in both medial temporal lobe structures and the neocortex is strongly associated with positive amyloid PET scans and with clinical impairment across the normal aging to dementia clinical spectrum [82,130–141].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the limited data currently available, tau PET ligand binding is linearly correlated with elevated CSF P-tau [82,83,115]; however, the correlation is imperfect.”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“we examined the influence of sex to modify the well-characterized cross-sectional association between regional tau PET and global Aβ PET.14–16”
From Sex Differences in the Association of Global Amyloid and Regional Tau Deposition Measured by Positron Emission Tomography in Clinically Normal Older Adults (2019) · cites this paper as [15]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“supports recent evidence that tau may play an early pathological role in Alzheimer’s disease129–131”
From Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing (2019) · cites this paper as [131]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression shrinkage and selection via the lasso
Tibshirani, R. (1996) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1996.tb02080.x · Cited by 51,482 · cited 2×
“The family of penalized regression fit here is the elastic net penalty (27): the L1 penalty component enforces sparsity (that is, many bs will be identically 0, not included in the model) (26), whereas the L2 penalty allows highly correlated variables to enter the model simultaneously (27).”
Regularization and Variable Selection Via the Elastic Net
Zou, H., & Hastie, T. (2005) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.1467-9868.2005.00503.x · Cited by 20,957
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Self-citationNeuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 3×
“The specificity of this relationship strengthens the argument that the identified relationships are disease-specific: elevated tau in the CSF is associated with tau deposition within regions known to be sensitive to AD-related tauopathy (2).”
InfluentialThe Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Self-citationAlzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155 · cited 2×
“Overlap with respect to CDR status likely represents the variable relationship between pathological burden and cognitive symptoms often attributed to differences in host factors, for example, cognitive reserve (8, 23).”
Self-citationOverdependence on degraded gist memory in Alzheimer's disease.
Gallo, D. A., Shahid, K. R., Olson, M. A., Solomon, T. M., Schacter, D. L., & Budson, A. E. (2006) · Neuropsychology · doi:10.1037/0894-4105.20.6.625 · Cited by 4,732
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496 · cited 2×
“The Aβ imaging literature has grown over the past decade (4), whereas tau imaging is a relatively new addition to the field.”
Jack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Research works printed but not linked: 1
- 50. Roussas GG A First Course in Mathematical Statistics Addison-Wesley Pub. Co. Reading, MA 1973
Cited by
Items 301–400 of 736
Joint associations of β-amyloidosis and cortical thickness with cognition
Knopman, D. S., Lundt, E. S., Therneau, T. M., Vemuri, P., Lowe, V. J., Kantarci, K., Gunter, J. L., Senjem, M. L., Mielke, M. M., Machulda, M. M., et al. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.01.017 · Cited by 30
“…dementia (Xia et al., 2017), the low tau PET signal outside of the medial temporal lobe in cognitively unimpaired individuals (Johnson et al., 2015; Brier et al., 2016; Cho et al., 2016; Ossenkoppele et al., 2016; Scholl et al., 2016; Schwarz et al., 2016a) will present unique challenges to…”
BackgroundChiu, M., Chen, T., Hu, C., Yan, S., Sun, Y., Liu, B.-H., Chang, Y.-T., Yang, C., & Yang, S. (2020) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2020.102182 · Cited by 36
PEG-Ceramide Nanomicelles Induce Autophagy and Degrade Tau Proteins in N2a Cells
Gao, J., Chen, X., Ma, T., He, B., Li, P., Zhao, Y., Ma, Y., Zhuang, J., & Yin, Y. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s258311 · Cited by 31
Long-Term Exposure to PM10 and in vivo Alzheimer’s Disease Pathologies
Lee, J. H., Byun, M. S., Yi, D., Ko, K., Jeon, S. Y., Sohn, B. K., Lee, J., Lee, Y., Joung, H., & Lee, D. Y. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200694 · Cited by 30
Tu, L., Lv, X., Fan, Z., Zhang, M., Wang, H., & Yu, X. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.586330 · Cited by 29
Boerwinkle, A. H., Wisch, J. K., Chen, C. D., Gordon, B. A., Butt, O. H., Schindler, S. E., Sutphen, C., Flores, S., Dincer, A., Benzinger, T. L. S., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000012123 · Cited by 28
Self-citationSeo, E. H., Lim, H. J., Yoon, H., Choi, K. Y., Lee, J. J., Park, J. Y., Choi, S. H., Kim, H., Kim, B. C., & Lee, K. H. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00909-1 · Cited by 31
The role of adenosine A2A receptors in Alzheimer's disease and tauopathies
Launay, A., Nebie, O., Shankara, J. V., Lebouvier, T., Buée, L., Faivre, É., & Blum, D. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109379 · Cited by 33
Mohammadi, Z., Alizadeh, H., Marton, J., & Cumming, P. D. (2023) · Biomolecules · doi:10.3390/biom13020290 · Cited by 30
Wang, Q., Schindler, S. E., Chen, G., McKay, N. S., McCullough, A. A., Flores, S. E., Liu, J., Sun, Z., Wang, S., Wang, W., et al. (2024) · Neurology · doi:10.1212/wnl.0000000000208013 · Cited by 32
Self-citationKetone body metabolism and the NLRP3 inflammasome in Alzheimer's disease
Shippy, D. C., Evered, A. H., & Ulland, T. K. (2024) · Immunological Reviews · doi:10.1111/imr.13365 · Cited by 36
Páez, A., Gillman, S. O., Dogaheh, S. B., Carnes, A., Dakterzada, F., Barbé, F., Dang‐Vu, T. T., & Ripoll, G. P. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14424 · Cited by 38
Cecchini, M. A., Yassuda, M. S., Squarzoni, P., Coutinho, A. M., Faria, D. D. P., Duran, F., da Costa, N. A., Porto, F. H. D. G., Nitríni, R., Forlenza, O. V., et al. (2021) · Brain and Cognition · doi:10.1016/j.bandc.2021.105749 · Cited by 29
Sensing red blood cell nano-mechanics: Toward a novel blood biomarker for Alzheimer’s disease
Nardini, M., Ciasca, G., Lauria, A., Rossi, C., Giacinto, F. D., Romanò, S., Santo, R. D., Papi, M., Palmieri, V., Perini, G., et al. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.932354 · Cited by 26
“Currently, Alzheimer’s disease (AD) diagnostics rely on cognitive testing supported by additional biomarkers, which include cerebrospinal fluid Aβ42, total and phosphorylated fulllength-tau or its truncated form, positron emission tomography (PET) of brain amyloid deposition and glucose metabolism, and brain atrophy o…”
BackgroundFurr, J. W., Morales‐Scheihing, D., Manwani, B., Lee, J., & McCullough, L. D. (2019) · NeuroMolecular Medicine · doi:10.1007/s12017-019-08568-0 · Cited by 29
Medawar, E., Benway, T. A., Liu, W., Hanan, T. A., Haslehurst, P., James, O. T., Yap, K., Muessig, L., Moroni, F., Nahaboo Solim, M. A., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2018.12.006 · Cited by 26
“Furthermore, in humans, cognitive decline correlates well with Tau PET markers and less with Aβ load [50].”
BackgroundThe Effects of Amyloid and Tau on Functional Network Connectivity in Older Populations
Wales, R. M., & Leung, H.-C. (2021) · Brain Connectivity · doi:10.1089/brain.2020.0902 · Cited by 26
“…to amyloid, tau levels (measured by cerebrospinal fluid [CSF] or positron emission tomography [PET]) are more closely related to cognitive decline (Brier et al., 2016; Johnson et al., 2016; Pontecorvo et al., 2017), brain volume loss (LaPoint et al., 2017; Maass et al., 2018), and…”
Gutman, B., Shmilovitch, A.-H., Aran, D., & Shelly, S. (2024) · JMIR Neurotechnology · doi:10.2196/59556 · Cited by 37
“In ASPECTS grading, a commercial software platform offering automated ASPECTS scoring demonstrated comparable performance to neuroradiologists in scoring ASPECTS on noncontrast CT scans in patients with acute stroke ( P .003) [175].”
Knopman, D. S., Jack, C. R., Lundt, E. S., Weigand, S. D., Vemuri, P., Lowe, V. J., Kantarci, K., Gunter, J. L., Senjem, M. L., Mielke, M. M., et al. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.06.003 · Cited by 26
“Although the availability of Tau-positron emission tomography (PET) imaging (Brier et al., 2016; Johnson et al., 2016; Scholl et al., 2016; Schwarz et al., 2016) offers a different route to understanding progression of disease in AD, structural magnetic resonance (MR) and 18fluorodeoxyglucose FDG…”
BackgroundYan, S., Zheng, C., Paranjpe, M. D., Li, J., Benzinger, T. L. S., Lu, J., & Zhou, Y. (2020) · Theranostics · doi:10.7150/thno.48522 · Cited by 28
Self-citationYue-Qin, Z., Gu, J.-H., Chen, L., Zhang, T., & Zhou, X. (2020) · Journal of Functional Foods · doi:10.1016/j.jff.2020.104324 · Cited by 28
Pan, F., Huang, Q., Wang, Y., Wang, Y., Guan, Y., Xie, F., & Guo, Q. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.832700 · Cited by 26
“Though the examination of cerebrospinal fluid (CSF) and PET imaging provide the most reliable AD-related biomarkers of Aβ and tau in vivo (Engelborghs et al., 2008; Brier et al., 2016), the invasive sampling procedure of CSF and high cost of PET image hinder their application in clinical trials and population screenin…”
BackgroundIn vivo [ 18 F]-AV-1451 tau-PET imaging in sporadic Creutzfeldt-Jakob disease
Day, G. S., Gordon, B. A., Perrin, R. J., Cairns, N. J., Beaumont, H., Schwetye, K., Ferguson, C., Sinha, N., Bucelli, R., Musiek, E. S., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000005064 · Cited by 26
Self-citationDiscerning the relationship between microglial activation and Alzheimer’s disease
Kreisl, W. C. (2017) · Brain · doi:10.1093/brain/awx151 · Cited by 24
First-in-Rat Study of Human Alzheimer’s Disease Tau Propagation
Smolek, T., Jadhav, S., Brezováková, V., Cubinkova, V., Valachova, B., Novák, P., & Žilka, N. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1102-0 · Cited by 32
Association between personality and tau-PET binding in cognitively normal older adults
Schultz, S. A., Gordon, B. A., Mishra, S., Su, Y., Morris, J. C., Ances, B. M., Duchek, J. M., Balota, D. A., & Benzinger, T. L. S. (2019) · Brain Imaging and Behavior · doi:10.1007/s11682-019-00163-y · Cited by 28
“Data were processed using a Freesurfer ROI approach as done in prior work using flortaucipir (Brier et al. 2016; Gordon et al. 2016; Schultz et al. 2018; Wang et al. 2016).”
BackgroundMethodSelf-citationBeaurain, M., Salabert, A., Ribeiro, M. J., Arlicot, N., Damier, P., Jeune, F. L., Démonet, J., & Payoux, P. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00268 · Cited by 27
“Several clinical studies have shown a close correlation between [18F]-AV1451 binding and the neuropathological stages of tau (122), cognitive decline and tau levels in cerebrospinal fluid (123, 124).”
BackgroundAlzheimer’s Disease in Down Syndrome: Progress in the Design and Conduct of Drug Prevention Trials
Rafii, M. S. (2020) · CNS Drugs · doi:10.1007/s40263-020-00740-6 · Cited by 26
“The abnormal hyperphosphorylation of tau protein leading to neurofibrillary tangles is seen later in the course of AD, both in the general population as well as in ADAD and DSAD, and correlates with the constellation of symptoms based on its regional location in the brain [26].”
BackgroundProvost, K., Iaccarino, L., Soleimani‐Meigooni, D. N., Baker, S. L., Edwards, L., Eichenlaub, U., Hansson, O., Jagust, W. J., Janabi, M., Joie, R. L., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-05152-8 · Cited by 27
Passive immunization against phosphorylated tau improves features of Huntington's disease pathology
Alpaugh, M., Masnata, M., de Rus Jacquet, A., Lepinay, E., Denis, H. L., Saint-Pierre, M., Davies, P., Planel, E., & Cicchetti, F. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.01.020 · Cited by 25
“Tau immunotherapy: Hopes and hindrances”
Shahpasand, K., Shamloo, A. S., Nabavi, S. M., Lu, K. P., & Zhou, X. Z. (2017) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1393594 · Cited by 29
Perani, D., Iaccarino, L., Lammertsma, A. A., Windhorst, A. D., Edison, P., Boellaard, R., Hansson, O., Nordberg, A. K., Jacobs, A. H., & IMBI Project (2019) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2019.02.004 · Cited by 27
Imaging Biomarkers of Alzheimer Disease in Multiple Sclerosis
Zeydan, B., Lowe, V. J., Reichard, R. R., Przybelski, S. A., Lesnick, T. G., Schwarz, C. G., Senjem, M. L., Gunter, J. L., Parisi, J. E., Machulda, M. M., et al. (2020) · Annals of Neurology · doi:10.1002/ana.25684 · Cited by 27
Half-curcumin analogues as PET imaging probes for amyloid beta species
Yang, J., Cheng, R., Fu, H., Yang, J., Kumar, M., Lu, J., Xu, Y., Liang, S. H., Cui, M., & Ran, C. (2019) · Chemical Communications · doi:10.1039/c8cc10166c · Cited by 25
Sun, Y., Ma, L., Cai, W., & Shao, X. (2020) · Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy · doi:10.1016/j.saa.2020.118046 · Cited by 24
Ahmed, T., der Jeugd, A. V., Caillierez, R., Buée, L., Blum, D., D’Hooge, R., & Balschun, D. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.570223 · Cited by 28
“Thus, it is Tau pathology and not Aβ-mediated functional deterioration that turned out to correlate better with the severity of dementia (Gomez-Isla et al., 1997; Braak et al., 1998; Nelson et al., 2012; Brier et al., 2016).”
BackgroundGuzmán‐Vélez, E., Zetterberg, H., Fox‐Fuller, J. T., Vila‐Castelar, C., Sanchez, J. S., Baena, A. Y., Garcia‐Ospina, G., Aguillon, D. F., Pardilla‐Delgado, E., Gatchel, J. R., et al. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12248 · Cited by 25
Neurofibrillary tau depositions emerge with subthreshold cerebral beta-amyloidosis in down syndrome
Zammit, M. D., Tudorascu, D. L., Laymon, C. M., Hartley, S. L., Ellison, P. A., Zaman, S. H., Ances, B. M., Johnson, S. C., Stone, C. K., Sabbagh, M. N., et al. (2021) · NeuroImage Clinical · doi:10.1016/j.nicl.2021.102740 · Cited by 25
“…in the classic studies of Braak and Braak (Lowe et al., 2018; Braak and Braak, 1997), that tau is highly associated with Aβ deposition and cognitive decline (Brier et al., 2016), and that tau PET can distinguish different clinical groups in the Alzheimer’s disease continuum (Johnson et al., 2016).”
BackgroundSelf-citationBilingualism as a Contributor to Cognitive Reserve: What it Can do and What it Cannot do
Berkes, M., & Bialystok, E. (2022) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/15333175221091417 · Cited by 33
Aschenbrenner, A. J., Gordon, B. A., Fagan, A. M., Schindler, S. E., Balota, D. A., Morris, J. C., & Hassenstab, J. J. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200018 · Cited by 24
Self-citationHojjati, S. H., Feiz, F., Ozoria, S., Razlighi, Q. R., & Initiative, F. T. A. D. N. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210419 · Cited by 25
“Our hypothesis, if true, will provide the underlying reason for the weak relationship between the A (cid:2) deposition and cognition [39], whereas its deposition level is shown to be strongly related to the FC of the DMN [21, 22, 25].”
Darmanthé, N., Initiative, A. D. N., Tabatabaei‐Jafari, H., & Cherbuin, N. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210092 · Cited by 23
Chang, C., Chang, Y., Chuang, P., Nguyen, T. N. A., Wu, K.-C., Chou, F.-Y., Cheng, S., Chen, H., Jin, L., Carvalho, K., et al. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01213-7 · Cited by 23
Cerebrospinal fluid and blood biomarkers in the diagnostic assays of Alzheimer’s disease
Zhang, L., Liang, X., Zhang, Z., & Luo, H. (2021) · Journal of Innovative Optical Health Sciences · doi:10.1142/s1793545822300014 · Cited by 24
Untangling the Role of Tau in Huntington’s Disease Pathology
Salem, S., & Cicchetti, F. (2023) · Journal of Huntington s Disease · doi:10.3233/jhd-220557 · Cited by 23
Tau PET Imaging for Staging of Alzheimer's Disease in Down Syndrome
Rafii, M. S. (2018) · Developmental Neurobiology · doi:10.1002/dneu.22658 · Cited by 24
“In the general population, tau pathology is a more proximal marker for cognitive decline in AD than amyloid pathology (Brier et al., 2016).”
BackgroundSmith, R. X., Strain, J. F., Tanenbaum, A., Fagan, A. M., Hassenstab, J. J., McDade, E., Schindler, S. E., Gordon, B. A., Xiong, C., Chhatwal, J. P., et al. (2021) · Brain Connectivity · doi:10.1089/brain.2020.0808 · Cited by 26
Self-citationSmith, G. S., Protas, H., Kuwabara, H., Savonenko, A., Nassery, N., Gould, N. F., Kraut, M., Avramopoulos, D., Holt, D., Dannals, R. F., et al. (2023) · NeuroImage: Clinical · doi:10.1016/j.nicl.2023.103322 · Cited by 22
Self-citationNadh, A. G., Revikumar, A., Sudhakaran, P. R., & Nair, A. S. (2022) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2022.105422 · Cited by 22
Dong, Q., Zhang, W., Stonnington, C. M., Wu, J., Gutman, B. A., Chen, K., Su, Y., Baxter, L. C., Thompson, P. M., Reiman, E. M., et al. (2020) · NeuroImage Clinical · doi:10.1016/j.nicl.2020.102338 · Cited by 26
Self-citationPET amyloid in normal aging: direct comparison of visual and automatic processing methods
Haller, S., Montandon, M., Lilja, J., Rodriguez, C. K., Garibotto, V., Herrmann, F. R., & Giannakopoulos, P. (2020) · Scientific Reports · doi:10.1038/s41598-020-73673-1 · Cited by 23
Targeting Tau to Treat Clinical Features of Huntington's Disease
Masnata, M., Salem, S., Jacquet, A. D. R., Anwer, M., & Cicchetti, F. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.580732 · Cited by 27
“Along these lines, data collected by Positron Emission Tomography (PET) have allowed to establish correlations between tau and cognitive decline, with tau deposits more closely related with cognitive dysfunction in AD patients than amyloid β (Aβ) (94).”
BackgroundChen, Y.-H., Lin, R.-R., Huang, H.-F., Xue, Y.-Y., & Tao, Q.-Q. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.848180 · Cited by 22
Meysami, S., Raji, C. A., Glatt, R. M., Popa, E. S., Ganapathi, A. S., Bookheimer, T., Slyapich, C. B., Pierce, K. P., Richards, C. J., Lampa, M. G., et al. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220886 · Cited by 25
Jiang, T., Dong, Y., Zhu, W., Wu, T., Chen, L., Cao, Y., Yu, X., Ye, P., Wang, L., Xiao, Y., et al. (2023) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2023.2240886 · Cited by 25
“Tau phosphorylation and amyloid-beta (Aβ) processing have been shown to play an early pathological role in neurodegenerative disease (Brier et al. 2016; Shi et al. 2017).”
P2X7 Receptor: an Emerging Target in Alzheimer’s Disease
Huang, Q., Ying, J., Yu, W., Dong, Y., Xiong, H., Zhang, Y., Liu, J., Wang, X., & Hua, F. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03699-9 · Cited by 30
“PET imaging is a recognized technique commonly used to diagnose brain diseases including Alzheimer’s disease [158].”
MethodLiu, Q., Wang, S., & Ding, K. (2017) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(17)30093-6 · Cited by 24
Eskandari-Sedighi, G., Daude, N., Gapeshina, H., Sanders, D. W., Kamali-Jamil, R., Yang, J., Shi, B., Wille, H., Ghetti, B., Diamond, M. I., et al. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0215-7 · Cited by 22
Tau Positron Emission Tomography in Autosomal Dominant Alzheimer Disease: Small Windows, Big Picture
McDade, E., & Bateman, R. J. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2017.4026 · Cited by 22
Continuous Monitoring of Tau-Induced Neurotoxicity in Patient-Derived iPSC-Neurons
Oakley, D. H., Klickstein, N., Commins, C., Chung, M., Dujardin, S., Bennett, R. E., Hyman, B. T., & Frosch, M. P. (2021) · The Journal of Neuroscience · doi:10.1523/jneurosci.2590-20.2021 · Cited by 18
Zinc utilization by microglia in Alzheimer’s disease
Shippy, D. C., Oliai, S. F., & Ulland, T. K. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107306 · Cited by 28
“There appears to be a connection between tau and A b AD pathogenesis, due to the strong correlation in A b plaque burden and the severity of tau pathology (24).”
BackgroundFalls Associate with Neurodegenerative Changes in ATN Framework of Alzheimer’s Disease
Keleman, A. A., Wisch, J. K., Bollinger, R. M., Grant, E., Benzinger, T. L. S., Morris, J. C., Ances, B. M., & Stark, S. L. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200192 · Cited by 25
Self-citationThe Beneficial Role of Natural Endocrine Disruptors: Phytoestrogens in Alzheimer’s Disease
Domańska, A., Orzechowski, A., Litwiniuk, A., Kalisz, M., Bik, W., & Baranowska-Bik, A. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/3961445 · Cited by 28
“The aforementioned processes inevitably lead to neurodegeneration [13].”
BackgroundInvestigating Tau and Amyloid Tracer Skull Binding in Studies of Alzheimer Disease
Flores, S. E., Chen, C. D., Su, Y., Dincer, A., Keefe, S., McKay, N. S., Paulick, A. M., Guzmán, G., Wang, L. Y., Hornbeck, R. C., et al. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.122.263948 · Cited by 23
Self-citationTau burden is best captured by magnitude and extent: Tau‐MaX as a measure of global tau
Brown, C., Das, S. R., Cousins, K. A. Q., Tropea, T. F., Plotkin, A., Detre, J. A., Yushkevich, P. A., McMillan, C. T., Lee, E. B., Shaw, L. M. J., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70346 · Cited by 19
Mason, E. J., Hussey, E. P., Molitor, R. J., Ko, P. C., Donahue, M. J., & Ally, B. A. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-160772 · Cited by 28
“This indicates that there was a learning effect in both groups, and although at-risk group was consistently less accurate than the control group, the two groups did not learn at different rates.”
Recent neuroimaging, neurophysiological, and neuropathological advances for the understanding of NPC
Benussi, A., Cotelli, M. S., Padovani, A., & Borroni, B. (2018) · F1000Research · doi:10.12688/f1000research.12361.1 · Cited by 20
Triana‐Baltzer, G., Kolen, K. V., Theunis, C., Moughadam, S., Slemmon, R., Mercken, M. H., Galpern, W. R., Sun, H. F., & Kolb, H. C. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200463 · Cited by 26
Han, C., Rundo, L., Murao, K., Milacski, Z. Á., Umemoto, K., Sala, E., Nakayama, H., & Satoh, S. (2020) · Lecture notes in computer science · doi:10.1007/978-3-030-63061-4_5 · Cited by 21
Barron, M. R., Gartlon, J. E., Dawson, L. A., Atkinson, P. J., & Pardon, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00293 · Cited by 20
PET Neuroimaging in Dementia Conditions
Perani, D., Caminiti, S. P., Carli, G., & Tondo, G. (2020) · Springer eBooks · doi:10.1007/978-3-030-53168-3_9 · Cited by 21
Raber, J., Perez, R., Torres, E. R. S., Krenik, D., Boutros, S. W., Patel, E. M., Chlebowski, A. C., Torres, E. R., Perveen, Z., Penn, A. L., et al. (2021) · Environmental Health Perspectives · doi:10.1289/ehp8428 · Cited by 20
Strain, J. F., Brier, M. R., Tanenbaum, A., Gordon, B. A., McCarthy, J. E., Dincer, A., Marcus, D. S., Chhatwal, J. P., Graff‐Radford, N. R., Day, G. S., et al. (2022) · NeuroImage · doi:10.1016/j.neuroimage.2022.119511 · Cited by 26
Self-citationTau protein plays a role in the mechanism of cognitive disorders induced by anesthetic drugs
Chen, Z., Wang, S., Meng, Z., Ye, Y., Shan, G., Wang, X., Zhao, X., & Jin, Y. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1145318 · Cited by 28
“, 2019), which may be an important starting factor for early memory decline, dementia and other symptoms and promote disease progression (Brier et al., 2016).”
BackgroundCognition and anatomy of adult Niemann–Pick disease type C: Insights for the Alzheimer field
Bergeron, D., Poulin, S. P., & Laforce, R. J. (2017) · Cognitive Neuropsychology · doi:10.1080/02643294.2017.1340264 · Cited by 21
“It is to be noted, however, that, in AD, amyloid plaques are diffuse and do not correlate with cognitive impairment, whereas NFTs strongly correlate with anatomical and cognitive abnormalities even in atypical presentations (Brier et al., 2016; Ossenkoppele et al., 2015).”
BackgroundThe Entorhinal Cortex Atrophy Score Is Diagnostic and Prognostic in Mild Cognitive Impairment
Traschütz, A., Enkirch, S. J., Polomac, N., Widmann, C. N., Schild, H. H., Heneka, M. T., & Hattingen, E. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-181150 · Cited by 23
Ghaffari, M. S., Sanadgol, N., & Abdollahi, M. R. (2020) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557520666200513122357 · Cited by 21
Clark, A. L., Weigand, A. J., Bangen, K. J., Thomas, K. R., Eglit, G. M. L., Bondi, M. W., Delano‐Wood, L., & Initiative, A. D. N. (2021) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12239 · Cited by 23
The Dichotomy of Alzheimer’s Disease Pathology: Amyloid-β and Tau
Ashford, J. W. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-181198 · Cited by 19
Wu, J., Dong, Q., Gui, J., Zhang, J., Su, Y., Chen, K., Thompson, P. M., Caselli, R. J., Reiman, E. M., Ye, J., et al. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.669595 · Cited by 22
“Beta-amyloid accumulation is a major of AD neuropathology (Brier et al., 2016; Cummings, 2019).”
BackgroundInfluentialSelf-citationWang, C., Ye, H., Zheng, Y., Qi, Y., Zhang, M., Long, Y., & Hu, Y. (2022) · NeuroMolecular Medicine · doi:10.1007/s12017-022-08717-y · Cited by 19
“The main pathological feature of AD is senile plaques, SP) formed by massive deposition of Aβ outside neurons (Brier et al., 2016; Xiao et al., 2015).”
BackgroundSolid-state NMR of paired helical filaments formed by the core tau fragment tau(297-391)
Al‐Hilaly, Y. K., Hurt, C., Rickard, J. E., Harrington, C. R., Storey, J. M. D., Wischik, C. M., Serpell, L. C., & Siemer, A. B. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.988074 · Cited by 19
“The presence of tau filaments is strongly correlated with dementia in tauopathies (Wilcock and Esiri, 1982; Arriagada et al., 1992; Mukaetova-Ladinska et al., 2000; Maruyama et al., 2013; Brier et al., 2016; Gomperts et al., 2016; Smith et al., 2016) and oligomeric tau species are implicated in the spread of tau aggre…”
BackgroundGallagher, R. L., Koscik, R., Moody, J. F., Vogt, N., Adluru, N., Kecskemeti, S., Hulle, C. V., Chin, N. A., Asthana, S., Kollmorgen, G., et al. (2023) · Alzheimer's Research & Therapy · doi:10.1186/s13195-023-01281-y · Cited by 19
Current status of PET tracers for the early diagnosis of Alzheimer's disease
Li, Y., Liu, T., Zeng, Q., & Cui, M. (2024) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2024.117546 · Cited by 20
Borreca, A., Latina, V., Corsetti, V., Middei, S., Piccinin, S., Valle, F. D., Bussani, R., Ammassari‐Teule, M., Nisticò, R., Calissano, P., et al. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-0974-3 · Cited by 18
Wu, P.-C., Fann, M., Tran, T. T., Chen, S.-C., Devina, T., Cheng, I. H.-J., Lien, C., Kao, L., Wang, S., Fuh, J., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-55614-9 · Cited by 18
Wan, J., Gong, Y., Xu, Z., Dong, X., Wei, G., & Zhang, Q. (2021) · Biophysical Chemistry · doi:10.1016/j.bpc.2021.106541 · Cited by 20
Frustrated peptide chains at the fibril tip control the kinetics of growth of amyloid-β fibrils
Xu, Y., Knapp, K., Le, K. N., Schafer, N. P., Safari, M. S., Davtyan, A., Wolynes, P. G., & Vekilov, P. G. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2110995118 · Cited by 20
“and dynamics study of amyloid beta peptide (1-42): An in-silico-based analysis to”
BackgroundHan, C., Rundo, L., Murao, K., Noguchi, T., Shimahara, Y., Milacski, Z. Á., Koshino, S., Sala, E., Nakayama, H., & Satoh, S. (2020) · arXiv (Cornell University) · doi:10.17863/cam.68695 · Cited by 19
Key biomarkers in Alzheimer’s disease: Insights for diagnosis and treatment strategies
Jamal, R., Shaikh, M. A., Taleuzzaman, M., Haque, Z., Albratty, M., Alam, M. S., Makeen, H. A., Zoghebi, K. A., & Saleh, S. F. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251330500 · Cited by 19
Plexin-A4 mediates amyloid-β–induced tau pathology in Alzheimer’s disease animal model
Chung, S., Yang, J., Kim, H. J., Hwang, E. M., Lee, W., Suh, K. Y., Choi, H., & Mook‐Jung, I. (2021) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2021.102075 · Cited by 20
“The NFT burden positively correlates with neuronal loss; interestingly, the severity of tau pathology is more closely associated with the degree of cognitive impairment than that of Aβ (Arriagada et al., 1992; Brier et al., 2016; Murray et al., 2015; Nelson et al., 2012).”
BackgroundZhang, X., Zou, L. B., Meng, L., Xiong, M., Pan, L., Chen, G., Zheng, Y., Xiong, J., Wang, Z., Duong, D. M., et al. (2021) · eLife · doi:10.7554/elife.65301 · Cited by 19
Identification and analysis of a selective DYRK1A inhibitor
Lin, T. E., Chao, M., HuangFu, W., Tu, H., Peng, Z., SU, C., Sung, T.-Y., Hsieh, J., Lee, C., Yang, C., et al. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112580 · Cited by 19
Marsool, M. D. M., Prajjwal, P., Reddy, Y. B., Marsool, A. D. M., Lam, J. R., & Nandwana, V. (2023) · Disease-a-Month · doi:10.1016/j.disamonth.2023.101547 · Cited by 24
Involvement of inflammasomes in the pathogenesis of Alzheimer's disease
Beder, N., Belkhelfa, M., & Leklou, H. (2024) · Journal of Alzheimer s Disease · doi:10.1177/13872877241283677 · Cited by 22
“9,10 A β and tau proteins are the speci fi c biomarkers used for AD diagnosis, and they are becoming increasingly important in re fi ning the differential diagnosis by enabling in vivo detection and quanti fi cation.”
Inhaled Xenon Washout as a Biomarker of Alzheimer’s Disease
Hane, F. T., Li, T., Plata, J. A., Hassan, A. A., Granberg, K., & Albert, M. S. (2018) · Diagnostics · doi:10.3390/diagnostics8020041 · Cited by 21
Initiative, A. D. N., Li, Y., Yao, Z., Yu, Y., Zou, Y., Fu, Y., & Hu, B. (2019) · BMC Psychiatry · doi:10.1186/s12888-019-2149-9 · Cited by 18
Recent Advances in Imaging of Preclinical, Sporadic, and Autosomal Dominant Alzheimer's Disease
Buckley, R. F. (2021) · Neurotherapeutics · doi:10.1007/s13311-021-01026-5 · Cited by 18
Improving Mouse Models for Dementia. Are All the Effects in Tau Mouse Models Due to Overexpression?
Joel, Z., Izquierdo, P., Salih, D. A. M., Richardson, J. C., Cummings, D. M., & Edwards, F. A. (2018) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2018.83.037531 · Cited by 20
“However, in man, the development of sufficient cognitive deficits to result in diagnosis of the disease does not occur without the development of a substantial tangle load and neurodegeneration (Ridha et al. 2006; Brier et al. 2016).”
BackgroundChalatsa, I., Arvanitis, D. A., Mikropoulou, E. V., Giagini, A. T., Papadopoulou‐Daifoti, Z., Aligiannis, N., Halabalaki, M., Tsarbopoulos, A., Skaltsounis, A., & Sanoudou, D. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170862 · Cited by 19
Metadata
- Authors
- Brier, M. R., Gordon, B., Friedrichsen, K., McCarthy, J., Stern, A., Christensen, J., Owen, C., Aldea, P., Su, Y., Hassenstab, J., Cairns, N. J., Holtzman, D. M., Fagan, A. M., Morris, J. C., Benzinger, T. L. S., & Ances, B. M.
- Affiliations
- Washington University in St. Louis (US)
- Corresponding author
- Benzinger, Tammie L. S.
- Ances, Beau M.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2016-05-11
- Volume
- 8
- Issue
- 338
- Pages
- 338ra66-338ra66
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC5267531
- OpenAlex
- W2353776455
- Cited by
- 734
- References
- 56
- Citations by year
- 2026: 40 · 2025: 60 · 2024: 58 · 2023: 69 · 2022: 64 · 2021: 90 · 2020: 101 · 2019: 80 · 2018: 73 · 2017: 75 · 2016: 23
- FWCI
- 74.35
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion, cc-by)
- PubMed Central (acceptedVersion, cc-by)
- Open Scholarship Institutional Repository (Washington University in St. Louis) (submittedVersion)
- Funders
- NIH (P50AG05681, P01AG003991, P01AG026276, 5P30NS048056, 2UL1TR000448, 5RO1AG04343404)
- NSF (DMS1300280)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- Alzheimer's disease, tau PET imaging, cerebrospinal fluid tau, temporal lobe, preclinical Alzheimer's disease, cognitive performance, disease progression, neurofibrillary tangles, neuritic plaques
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Brain, Cognition, Female, Humans, Male, Peptide Fragments, Amyloid beta-Peptides, tau Proteins, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.